These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 38323311)

  • 61. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 62. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 63. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
    Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
    Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
    Roux C; Jafari SM; Shinde R; Duncan G; Cescon DW; Silvester J; Chu MF; Hodgson K; Berger T; Wakeham A; Palomero L; Garcia-Valero M; Pujana MA; Mak TW; McGaha TL; Cappello P; Gorrini C
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4326-4335. PubMed ID: 30770442
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
    Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
    [TBL] [Abstract][Full Text] [Related]  

  • 66. AZD1775 and anti-PD-1 antibody synergistically sensitize hepatoma to radiotherapy.
    Yin Y; Wang J; Yi J; Zhang K; Yin Z; Jin S; Zheng B
    Chin Med J (Engl); 2024 Jan; 137(2):222-231. PubMed ID: 38167245
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma.
    Qu T; Zhang W; Yan C; Ren D; Wang Y; Guo Y; Guo Q; Wang J; Liu L; Han L; Li L; Huang Q; Cao L; Ye Z; Zhang B; Zhao Q; Cao W
    J Transl Med; 2023 May; 21(1):341. PubMed ID: 37217923
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
    Fucikova J; Becht E; Iribarren K; Goc J; Remark R; Damotte D; Alifano M; Devi P; Biton J; Germain C; Lupo A; Fridman WH; Dieu-Nosjean MC; Kroemer G; Sautès-Fridman C; Cremer I
    Cancer Res; 2016 Apr; 76(7):1746-56. PubMed ID: 26842877
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
    Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
    Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity.
    Sequeira GR; Sahores A; Dalotto-Moreno T; Perrotta RM; Pataccini G; Vanzulli SI; Polo ML; Radisky DC; Sartorius CA; Novaro V; Lamb CA; Rabinovich GA; Salatino M; Lanari C
    Cancer Res; 2021 Mar; 81(5):1375-1387. PubMed ID: 33268529
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8
    Qian J; Chen T; Wu Q; Zhou L; Zhou W; Wu L; Wang S; Lu J; Wang W; Li D; Xie H; Su R; Guo D; Liu Z; He N; Yin S; Zheng S
    Cancer Lett; 2020 Dec; 495():1-11. PubMed ID: 32949680
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
    Li Y; Zhang H; Li Q; Zou P; Huang X; Wu C; Tan L
    Cancer Lett; 2020 Dec; 495():12-21. PubMed ID: 32941949
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
    Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
    Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
    [No Abstract]   [Full Text] [Related]  

  • 79. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.
    Mehla K; Tremayne J; Grunkemeyer JA; O'Connell KA; Steele MM; Caffrey TC; Zhu X; Yu F; Singh PK; Schultes BC; Madiyalakan R; Nicodemus CF; Hollingsworth MA
    Cancer Immunol Immunother; 2018 Mar; 67(3):445-457. PubMed ID: 29204701
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
    Markosyan N; Chen EP; Evans RA; Ndong V; Vonderheide RH; Smyth EM
    Breast Cancer Res; 2013; 15(5):R75. PubMed ID: 24004819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.